Randomized trial · people

Amycretin: side effects all mild or moderate in first human trial

Checked against the paper Randomized trialPublished by PepVault

The takeaway

This is the first human safety data for oral amycretin. Side effects were mild or moderate and mostly gut-related, but the study does not establish how much weight the drug takes off.

Kind
Randomized trial
Studied in
People
Number studied
144
Published
2025
Journal
Lancet

What they tested

The team tested whether amycretin tablets, a single molecule that acts on both GLP-1 and amylin receptors, were safe and well tolerated in people for the first time, and how the drug's blood levels behaved across doses.

How the study was done

A randomized, double-blind, placebo-controlled phase 1 trial in 144 adults aged 18-55 with overweight or obesity at one research site in San Antonio, Texas. It had three parts: single doses from 1 mg to 25 mg, daily doses of 3 mg, 6 mg or 12 mg for 10 days, and a 12-week regimen with doses stepped up as high as 2 × 50 mg a day, each compared against placebo (a dummy tablet).

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking amycretin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Across all parts, 89 (62%) of 144 people had at least one adverse event, meaning any health problem that came up during the study, with 364 events in total. Every event was mild or moderate, and events became more common at higher doses. Gastrointestinal events were the most common type, making up 180 (49%) of the 364 events and affecting 72 (81%) of the 89 people who had any event. There were no deaths, and amycretin blood levels rose in proportion to the dose.

What it doesn’t show

This was a small, early safety trial at a single site, lasting at most 12 weeks of treatment. Its main goal was safety rather than weight loss. Weight and blood sugar were only exploratory measures, and the study was funded by Novo Nordisk.

The paper

Gasiorek et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. Lancet. 2025.

The compound

More studies on Amycretin

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking amycretin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo